As a note of caution, it should be mentioned that all RA patients received disease-modifying therapies, which were divided into three classes due to their mode of action (conventional, black diamonds; TNFα inhibitors, grey diamonds; rituximab, white diamonds; Supplementary Figure S2A-B in Additional file 2). This evidence concerns the gene TNF and rheumatoid arthritis.